Azafaros raises $146M Series B to advance nizubaglustat into Phase 3 trials for rare lysosomal storage disorders, with ...

President Donald Trump on Monday made a sweeping promise to bring down drug prices and stop pharma companies from taking ...

House tax bill includes PBM reforms, spread pricing restrictions & orphan drug negotiation changes, with Rep. Guthrie leading ...

Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes ...

Vir Biotech's hepatitis B therapy shows 4% cure rate with doublet (tobevibart/elebsiran) and 10% with triplet therapy, below ...

Roche said its $50 billion promise to expand its manufacturing footprint in the US has the potential to be 'reassessed.' ...

New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...

Pres­i­dent Don­ald Trump said he’ll take ex­ec­u­tive ac­tion to have the US pay no more than oth­er coun­tries for drugs, a ...

FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.

How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a ...

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...